Table 2 EC50 values of cixutumumab, cixutumumab-PEG6-DM1-Low and cixutumumab-PEG6-DM1-High on MCF-7/Her18 breast cancer cells.

From: Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer

Immunoconjugates

EC50 (nM)b

Cixutumumab

47.1 ± 0.8

cixutumumab-PEG6-DM1-Low

20.4 ± 0.8

cixutumumab-PEG6-DM1-High

39.7 ± 0.4

  1. The potency of the conjugates was estimated by plotting the increased cytotoxic red intensity as a function of cell death against concentration. Sigmoidal dose response curves (variable slope) were generated GraphPad Prism V. 5.02 (GraphPad Software Inc.). Values are the mean of triplicates of at least two independent experiments.
Back to article page